SUBSCRIBE
SUBSCRIBE
News   Policy

Aspreva Pharmaceuticals Corporation Halts CellCept Filing

September 10, 2007 | 
1 min read
NEW YORK - Shares of Aspreva Pharmaceuticals Corp. fell 6 percent in Monday morning trading after the company and partner Roche said they won't move forward with a regulatory submission for CellCept as a first-step therapy for lupus nephritis.
Regulatory
MORE ON THIS TOPIC
World Management Team in office silhouette 3d rendering
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
 · 
6 min read
 · 
Lori Ellis
Contemporary art collage. Giang hand kicking office worker symbolizing dismissal. Unsuccessful employee. Job reduction. Concept of business, career, failure, success, troubles
Rare diseases
Ultragenyx Takes Second Hit as FDA Rejects Gene Therapy for Sanfilippo Syndrome
July 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Regulatory
FDA Mulls Speedier Reviews to Companies Willing To Lower Drug Costs
July 14, 2025
 · 
1 min read
 · 
Tristan Manalac
Contemporary art collage showing a hand giving a thumbs down surrounded by red arrows pointing down, concept of negative feedback and bad review
Complete response letters
Capricor Plunges on FDA Rejection of DMD Cell Therapy
July 11, 2025
 · 
3 min read
 · 
Tristan Manalac